Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $58.00 (59.47% upside)

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Show:
DateFirmActionRatingPrice TargetDetailsShare
10/30/2013FBR & CoInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR Capital MarketsInitiated CoverageOutperform$58.00ViewTweet This Rating  Share This Rating on StockTwits
10/25/2013Bank of AmericaInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
9/17/2013JPMorgan Chase & Co.Boost Price TargetOverweight$34.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Cowen and CompanyReiterated RatingBuy$50.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Leerink SwannBoost Price Target$34.00 -> $50.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Goldman SachsInitiated CoverageNeutral$37.00ViewTweet This Rating  Share This Rating on StockTwits
9/6/2013Cowen and CompanyInitiated CoverageOutperform$50.00ViewTweet This Rating  Share This Rating on StockTwits
8/7/2013Leerink SwannBoost Price Target$28.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
8/7/2013JPMorgan Chase & Co.Boost Price Target$30.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
5/14/2013Lazard LtdLower Price TargetBuy$33.00 -> $32.00ViewTweet This Rating  Share This Rating on StockTwits
5/4/2013Ativo ResearchInitiated CoverageMost UnfavorableViewTweet This Rating  Share This Rating on StockTwits
11/5/2012JPMorgan Chase & Co.Initiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
11/5/2012Lazard LtdInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
11/5/2012Leerink SwannInitiated CoverageOutperform$28.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2012Goldman SachsInitiated CoverageNeutral$23.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/30/2012 forward)
Discuss Kythera Biopharmaceuticals